[1]
|
Hirsch, I. (2005) Insulin analogues. The New England Journal of Medicine, 352, 174-183.
doi:10.1056/NEJMra040832
|
[2]
|
Lepore, M., Pampanelli, S., Fanelli, C., et al. (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 49, 2142-2148. doi:10.2337/diabetes.49.12.2142
|
[3]
|
Heinemann, L., Linkeschova, R., Rave, K., et al. (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care, 23, 644-649.
doi:10.2337/diacare.23.5.644
|
[4]
|
Clement, S. and Bowen-Wright, H. (2002) Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: A case report. Diabetes Care, 25, 1479-1480. doi:10.2337/diacare.25.8.1479-a
|
[5]
|
American Diabetes Association. (2008) Standards of medical care in diabetes—2008. Diabetes Care, 31, S12-S54.
|
[6]
|
Owen, W.E. and Roberts, W.L. (2004) Cross-reactivity of three recombinant insulin analogues with five commercial insulin immunoassays. Clinical Chemistry, 50, 257-259.
doi:10.1373/clinchem.2003.026625
|
[7]
|
Albright, E.S., Desmond, R. and Bell, D.S.H. (2004) Efficacy of Conversion from bedtime NPH insulin injecttion to onceor twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care, 27, 632-633. doi:10.2337/diacare.27.2.632
|
[8]
|
Ashwell, S.G., Gebbie, J. and Home, P.D. (2006) Twicedaily compared to once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabetic Medicine, 23, 879-886.
doi:10.1111/j.1464-5491.2006.01913.x
|